title: Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease.
abstract: It has been reported that antibodies reactive with peptide RSANFTDNAKTIIVQLNQSVEIN (peptide NTM) derived from the C-terminus of the second conserved domain of HIV-1 envelope glycoprotein gp120 could represent an important factor in control of the HIV disease. In order to check this notion we (i) tested reactivity with peptide NTM serum samples collected from 310 consecutive HIV-1 infected patients with a CD4(+) lymphocyte count ranging from 10 to 800/microL and (ii) performed the longitudinal study that included 107 sera samples collected from 29 HIV patients. Results of these studies demonstrated correlation between presence of anti-NTM antibodies in sera of HIV patients and disease progression measured by the CD4(+) cell count. Based on these findings we proposed the anti-NTM antibodies as useful prognostic marker for HIV disease.
authors.affiliation: Laboratory for Multidisciplinary Research, Institute of Nuclear Sciences, P.O.Box 522, 11001 Belgrade, Serbia and Montenegro. druid@beotel.yu
authors.forename: Nevena
authors.initials: N
authors.lastname: Veljkovic
authors.forename: Donald R
authors.initials: DR
authors.lastname: Branch
authors.forename: Radmila
authors.initials: R
authors.lastname: Metlas
authors.forename: Jelena
authors.initials: J
authors.lastname: Prljic
authors.forename: Roberto
authors.initials: R
authors.lastname: Manfredi
authors.forename: William W
authors.initials: WW
authors.lastname: Stringer
authors.forename: Veljko
authors.initials: V
authors.lastname: Veljkovic
mesh_terms: D015415:Biomarkers; D015704:CD4 Antigens / Q000276:immunology; D018791:CD4 Lymphocyte Count; D017124:Conserved Sequence / Q000276:immunology; D015195:Drug Design; D004797:Enzyme-Linked Immunosorbent Assay; D015483:HIV Antibodies / Q000276:immunology* / Q000627:therapeutic use; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D006801:Humans; D008137:Longitudinal Studies; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry / Q000276:immunology; D017434:Protein Structure, Tertiary / Q000502:physiology*
chemical_list: D015415:Biomarkers; D015704:CD4 Antigens; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D010455:Peptides